Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: Effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 9, 2016, Pages 1608-1616

  Jacques, Carlos Eduardo Diaz ^a,b   Donida, Bruna ^a,b   Mescka, Caroline P ^b   Rodrigues, Daiane G B ^a,b   Marchetti, Desirèe P ^a,b   Bitencourt, Fernanda H ^a,b   Burin, Maira G ^b   de Souza, Carolina F M ^b   Giugliani, Roberto ^a,b   Vargas, Carmen Regla ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Enzyme replacement therapy; Mucopolysaccharidosis type II; Oxidative stress; Pro inflammatory cytokines; Reactive nitrogen species; Reactive oxygen species

Indexed keywords

15 F2T ISOPROSTANE; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; CATALASE; CYTOKINE; DITYROSINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE; INTERLEUKIN 1BETA; ISOPROSTANE DERIVATIVE; NITRATE; NITRIC OXIDE; NITRITE; REACTIVE NITROGEN SPECIES; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPLACEMENT; ERYTHROCYTE; HUMAN; HUNTER SYNDROME; LIPID PEROXIDATION; LONG TERM CARE; MALE; NITRATIVE STRESS; OXIDATIVE STRESS; PRIORITY JOURNAL; SCHOOL CHILD; URINALYSIS; URINE LEVEL; YOUNG ADULT;

EID: 84975091210     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.05.021     Document Type: Article

References (82)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill Inc., New York. eighth ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Tuschl K., Gal A., Paschke E., Kircher S., Bodamer O.A. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr. Neurol. 2005, 32:270-272.
3. Guillén-Navarro E., Domingo-Jiménez M.R., Alcalde-Martín C., Cancho-Candela R., Couce M.L., Galán-Gómez E., Alonso-Luengo O. Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study. Orphanet J. Rare Dis. 2013, 8:92.
4. Piña-Aguilar R.E., Zaragoza-Arévalo G.R., Rau I., Gal A., Alcántara-Ortigoza M.A., López-Martínez M.S., Santillán-Hernández Y. Mucopolysaccharidosis type II in a female carrying a heterozygous stop mutation of the iduronate-2-sulfatase gene and showing a skewed X chromosome inactivation. Eur. J. Med. Genet. 2013, 56:159-162.
5. Vieira T., Schwartz I., Muñoz V., Pinto L., Steiner C., Ribeiro M., Boy R., Ferraz V., de Paula A., Kim C., Acosta A., Giugliani R. Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis?. Am. J. Med. Genet. A 2008, 146:1741-1747.
6. Martin R., Beck M., Eng C., Giugliani R., Harmatz P., Munoz V., Muenzer J. Recognition and diagnosis of mucopolysaccharidosis II (hunter syndrome). Pediatrics 2008, 121:377-386.
7. Young I.D., Harper P.S., Newcombe R.G., Archer I.M. A clinical and genetic study of Hunter's syndrome 2: differences between the mild and severe forms. J. Med. Genet. 1982, 19:408-411.
8. Poupětová H., Ledvinová J., Berná L., Dvořaková L., Kožich V., Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J. Inherit. Metab. Dis. 2010, 33:387-396.
9. Nelson J., Crowhurst J., Carey B., Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am. J. Med. Genet. A 2003, 123:310-313.
10. Baehner F., Schmiedeskamp C., Krummenauer F., Miebach E., Bajbouj M., Whybra C., Kohlschutter A., Kampmann C., Beck M. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J. Inherit. Metab. Dis. 2005, 28:1011-1017.
11. Pinto R., Caseiro C., Lemos M., Lopes L., Fontes A., Ribeiro H., Pinto E., Silva E., Rocha S., Marcão A., Ribeiro I., Lacerda L., Ribeiro G., Amaral O., Sá Miranda M.C. Prevalence of lysosomal storage diseases in Portugal. Eur. J. Hum. Genet. 2004, 12:87-92.
12. Poorthuis B.J., Wevers R.A., Kleijer W.J., Groener J.E., de Jong J.G., van Weely S., Niezen-Koning K.E., van Diggelen O.P. The frequency of lysosomal storage diseases in The Netherlands. Hum. Genet. 1999, 105:151-156.
13. Coelho J.C., Wajner M., Burin M.G., Vargas C.R., Giugliani R. Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism. Eur. J. Pediatr. 1997, 156:650-654.
14. Okuyama T., Tanaka A., Suzuki Y., Ida H., Tanaka T., Cox G.F., Eto Y., Orii T. Japan Elaprase® treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II). Mol. Genet. Metab. 2010, 99:18-25.
15. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 2006, 8:465-473.
16. Muenzer J., Gucsavas-Calikoglu M., McCandless S.E., Schuetz T.J., Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol. Genet. Metab. 2007, 90:329-337.
17. Wraith J.E., Scarpa M., Beck M., Bodamer O.A., De Meirleir L., Guffon N., Lund A.M., Malm G., Van der Ploeg A.T., Zeman J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur. J. Pediatr. 2008, 167:267-277.
18. Muenzer J., Beck M., Giugliani R., Suzuki Y., Tylki-Szymanska A., Valayannopoulo V., Vellodi A., Wraith J.E. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet. Med. 2011, 13:102-109.
19. Lampe C., Atherton A., Burton B.K., Descartes M., Giugliani R., Horovitz D.D., Kyosen S.O., Magalhães T.S., Martins A.M., Mendelsohn N.J., Muenzer J., Smith L.D. Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age. JIMD Rep. 2014, 14:99-113.
20. Giugliani R., Hwu W.L., Tylki-Szymanska A., Whiteman D.A., Pano A. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genet. Med. 2014, 16:435-441.
21. Filippon L., Vanzin C.S., Biancini G.B., Pereira I.N., Manfredini V., Sitta A., Peralba M.C.R., Schwartz I.V.D., Giugliani R., Vargas C.R. Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy. Mol. Genet. Metab. 2011, 103:121-127.
22. Pereira V.G., Martins A.M., Micheletti C., D'Almeida V. Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy. Clin. Chim. Acta 2008, 387:75-79.
23. Donida B., Marchetti D.P., Biancini G.B., Deon M., Manini P.R., da Rosa H.T., Moura D.J., Saffi J., Bender F., Burin M.G., Coitinho A.S., Giugliani R., Vargas C.R. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim. Biophys. Acta 2015, 1852:1012-1019.
24. Barschak A.G., Sitta A., Deon M., de Oliveira M.H., Haeser A., Dutra-Filho C.S., Wajner M., Vargas C.R. Evidence that oxidative stress is increased in plasma from patients with maple syrup urine disease. Metab. Brain Dis. 2006, 21:279-286.
25. Sitta A., Barschak A.G., Deon M., de Mari J.F., Barden A.T., Vanzin C.S., Biancini G.B., Schwartz I.V.D., Wajner M., Vargas C.R. l-Carnitine blood levels and oxidative stress in treated phenylketonuric patients. Cell. Mol. Neurobiol. 2009, 29:211-218.
26. Terman A., Kurz T., Gustafsson B., Brunk U.T. Lysosomal labilization. IUBMB Life 2006, 58:531-539.
27. Terman A., Brunk U.T. Oxidative stress, accumulation of biological 'garbage', and aging. Antioxid. Redox Signal. 2006, 8:197-204.
28. Villani G.R.D., Di Domenico C., Musella A., Cecere F., Di Napoli D., Di Natale P. Mucopolysaccharidosis IIIB: oxidative damage and cytotoxic cell involvement in the neuronal pathogenesis. Brain Res. 2009, 1279:99-108.
29. Halliwell B. Reactive species and antioxidants redox biology is a fundamental theme of aerobic life. Plant Physiol. 2006, 141:312-322.
30. Ohmi K., Greenberg D.S., Rajavel K.S., Ryazantsev S., Li H.H., Neufeld E.F. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1902-1907.
31. Archer L.D., Langford-Smith K.J., Bigger B.W., Fildes J.E. Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. J. Inherit. Metab. Dis. 2014, 37:1-12.
32. Filippon L., Wayhs C.A., Atik D.M., Manfredini V., Heber S., Carvalho C.G., Schwartz I.V.D., Giugliani R., Vargas C.R. DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients: protective effect of enzyme replacement therapy. Mutat. Res. 2011, 721:206-210.
33. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
34. Levine R.L., Garland D., Oliver C.N., Amici A., Climent L., Lenz A.G., Ahn B.W., Shalthiel S., Stadman E.R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990, 186:464-478.
35. Aksenov M.Y., Markesbery W.R. Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease. Neurosci. Lett. 2001, 302:141-145.
36. Kirschbaum B. Correlative studies of urine fluorescence and free radical indicators. Clin. Nephrol. 2002, 58:344-349.
37. Aebi H. Catalase in vitro. Methods Enzymol. 1984, 105:121-126.
38. Carlberg I., Mannervik B. Glutathione reductase. Methods Enzymol. 1985, 113:484-490.
39. Browne R.W., Armstrong D. Reduced glutathione and glutathione disulfide. Methods Mol. Biol. 1998, 108:347-352.
40. de Jong J.G.N., Wevers R.A., Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin. Chem. 1992, 38:803-807.
41. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
42. Futerman A.H., van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 2004, 5:554-565.
43. Vitner E.B., Platt F.M., Futerman A.H. Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem. 2010, 285:20423-20427.
44. Olsen R.K., Cornelius N., Gregersen N. Redox signalling and mitochondrial stress responses; lessons from inborn errors of metabolism. J. Inherit. Metab. Dis. 2015, 38:703-719.
45. Marinho H.S., Real C., Cyrne L., Soares H., Antunes F. Hydrogen peroxide sensing, signaling and regulation of transcription factors. Redox Biol. 2014, 2:535-562.
46. Higdon A., Diers A.R., Oh J.Y., Landar A., Darley-Usmar V.M. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem. J. 2012, 442:453-464.
47. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 2007, Oxford University Press, New York. fourth ed.
48. Evans P., Halliwell B. Free radicals and hearing: cause, consequence, and criteria. Ann. N. Y. Acad. Sci. 1999, 884:19-40.
49. Marchetti D.P., Donida B., da Rosa H.T., Manini P.R., Moura D.J., Saffi J., Deon M., Mescka C.P., Coelho D.M., Jardim L.B., Vargas C.R. Protective effect of antioxidants on DNA damage in leukocytes from X-linked adrenoleukodystrophy patients. Int. J. Dev. Neurosci. 2015, 43:8-15.
50. Deon M., Marchetti D.P., Donida B., Wajner M., Vargas C.R. Oxidative stress in patients with X-linked Adrenoleukodystrophy. Cell. Mol. Neurobiol. 2015, 1-16.
51. Sitta A., Ribas G.S., Mescka C.P., Barschak A.G., Wajner M., Vargas C.R. Neurological damage in MSUD: the role of oxidative stress. Cell. Mol. Neurobiol. 2014, 34:157-165.
52. Brunk U.T., Neuzil J., Eaton J.W. Lysosomal involvement in apoptosis. Redox Rep. 2001, 6:91-97.
53. Zhao M., Antunes F., Eaton J.W., Brunk U.T. Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur. J. Biochem. 2003, 270:3778-3786.
54. Terman A., Kurz T. Lysosomal iron, iron chelation, and cell death. Antioxid. Redox Signal. 2013, 18:888-898.
55. Biancini G.B., Vanzin C.S., Rodrigues D.B., Deon M., Ribas G.S., Barschak A.G., Manfredini V., Netto C.B.O., Jardim L.B., Giugliani R., Vargas C.R. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim. Biophys. Acta 2012, 1822:226-232.
56. Morrow J.D., Harris T.M., Roberts L.J. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal. Biochem. 1990, 184:1-10.
57. Lawson L.A., Rokach J., FitzGerald G.A. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem. 1999, 274:24441-24444.
58. Bourdon E., Blache D. The importance of proteins in defense against oxidation. Antioxid. Redox Signal. 2001, 3:293-311.
59. Dalle-Donne I., Aldini G., Carini M., Colombo R., Rossi R., Milzani A. Protein carbonylation, cellular dysfunction, and disease progression. J. Cell. Mol. Med. 2006, 10:389-406.
60. Mc Guire P.J., Parikh A., Diaz G.A. Profiling of oxidative stress in patients with inborn errors of metabolism. Mol. Genet. Metab. 2009, 98:173-180.
61. Lancaster J.R. Nitroxidative, nitrosative, and nitrative stress: kinetic predictions of reactive nitrogen species chemistry under biological conditions. Chem. Res. Toxicol. 2006, 19:1160-1174.
62. Malencik D.A., Anderson S.R. Dityrosine as a product of oxidative stress and fluorescent probe. Amino Acids 2003, 25:233-247.
63. Alvarez B., Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003, 25:295-311.
64. Quijano C., Alvarez B., Gatti R.M., Augusto O., Radi R. Pathways of peroxynitrite oxidation of thiol groups. Biochem. J. 1997, 322:167-173.
65. van der Vliet A., Eiserich J.P., O'Neill C.A., Halliwell B., Cross C.E. Tyrosine modification by reactive nitrogen species: a closer look. Arch. Biochem. Biophys. 1995, 319:341-349.
66. van der Vliet A., O'Neill C.A., Halliwell B., Cross C.E., Kaur H. Aromatic hydroxylation and nitration of phenylalanine and tyrosine by peroxynitrite. Evidence for hydroxyl radical production from peroxynitrite. FEBS Lett. 1994, 339:89-92.
67. Ischiropoulos H., Al-Mehdi A.B. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett. 1995, 364:279-282.
68. Minotti G., Aust S.D. Redox cycling of iron and lipid peroxidation. Lipids 1992, 27:219-226.
69. Braughler J.M., Duncan L.A., Chase R.L. The involvement of iron in lipid peroxidation. Importance of ferric to ferrous ratios in initiation. J. Biol. Chem. 1986, 261:10282-10289.
70. Rice-Evans C., Miller N.J. Total antioxidant status in plasma and body fluids. Methods Enzymol. 1994, 234:279-293.
71. + radical cation assay. Free Radic. Res. 1997, 26:195-199.
72. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., Schuchman E.H. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 2008, 172:112-122.
73. Arfi A., Richard M., Gandolphe C., Bonnefont-Rousselot D., Thérond P., Scherman D. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol. Genet. Metab. 2011, 103:18-25.
74. Villani G.R.D., Gargiulo N., Faraonio R., Castaldo S., Reyero E.G., DiNatale P. Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J. Neurosci. Res. 2007, 85:612-622.
75. Polgreen L.E., Vehe R.K., Rudser K., Kunin-Batson A., Utz J.J., Dickson P., Shapiro E., Whitley C.B. Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II and VI. Mol. Genet. Metab. 2016, 117:427-430.
76. Raykova V.D., Glibetic M., Ofenstein J.P., Aranda J.V. Nitric oxide-dependent regulation of pro-inflammatory cytokines in group B streptococcal inflammation of rat lung. Ann. Clin. Lab. Sci. 2003, 33:62-67.
77. Groeneveld P.H., Kwappenberg K.M., Langermans J.A., Nibbering P.H., Curtis L. Relation between pro- and anti-inflammatory cytokines and the production of nitric oxide (NO) in severe sepsis. Cytokine 1997, 9:138-142.
78. Hong Y.B., Kim E.Y., Jung S.C. Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse. J. Korean Med. Sci. 2006, 21:733-738.
79. Kobayashi Y. The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J. Leukoc. Biol. 2010, 88:1157-1162.
80. Connelly L., Palacios-Callender M., Ameixa C., Moncada S., Hobbs A.J. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J. Immunol. 2001, 166:3873-3881.
81. Jacobs A.T., Ignarro L.J. Nuclear factor-kappa B and mitogen-activated protein kinases mediate nitric oxide-enhanced transcriptional expression of interferon-beta. J. Biol. Chem. 2003, 278:18-27.
82. Negretto G.W., Deon M., Biancini G.B., Burin M.G., Giugliani R., Vargas C.R. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy. Cell Biol. Toxicol. 2014, 30:189-193.